1. YAP/TAZ Signaling and Resistance to Cancer Therapy
   Chan D.K. Nguyen et al, 2019, Trends in Cancer CrossRef
2. Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy
   Francesca Reggiani et al, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
3. Differentiation-inducing factor-1 inhibits EMT by proteasomal degradation of TAZ and YAP in cervical and colon cancer cell lines
   Masaki Arioka et al, 2025, European Journal of Pharmacology CrossRef
4. PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3
   Tinghua Hu et al, 2019, Journal of Drug Targeting CrossRef
5. Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy
   Yan Baglo et al, 2020, Photochemistry and Photobiology CrossRef
6. miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer
   Dongmei Li et al, 2021, Molecular Medicine Reports CrossRef
7. Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: Mechanisms and therapeutic potential
   Hadi Alizadeh et al, 2025, European Journal of Pharmacology CrossRef
8. Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein
   Wenjia Ma et al, 2019, Aging CrossRef
9. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR‐497‐5p/mTOR
   Zhibo Hou et al, 2021, Cancer Science CrossRef
10. YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas
    Wei Xu et al, 2021, Cancer Cell International CrossRef